Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 2
Submit an article Journal homepage
154
Views
47
CrossRef citations to date
0
Altmetric
Drug Evaluation

Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1

Gregory M Pastores Neurogenetics Unit, Department of Neurology and Pediatrics, New York University School of Medicine, New York, USA. [email protected]
&
Natalie L Barnett Neurogenetics Unit, Department of Neurology and Pediatrics, New York University School of Medicine, New York, USA. [email protected]
Pages 273-281 | Published online: 02 Mar 2005

Bibliography

  • BEUTLER E: Gaucher disease. Arch. Intern. Med. (1999) 159(8):881–882.
  • WEINREB NJ, CHARROW J, ANDERSSON HC et al: Effectiveness of enzyme replacement therapy in 1028 patients with Type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. I Med. 113(2):112–119.
  • VELLODI A, BEMBI B, De VILLEMEUR TB et al: Neuronopathic Gaucher Disease Task Force of the European Working Group on Gaucher Disease Management of Neuronopathic Gaucher disease: a European consensus. j Inherit. Metab. Dis. 24(3):319–327.
  • ERIKSON A, BEMBI B, SCHIFFMANN R: Neuronopathic forms of Gaucher's disease. Ba/1Iiere Gun. Haematol. 10(4):711–723.
  • DAMIANO AM, PASTORES GM, WARE JE Jr: The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Qual. Life Res. 7(5):373–386.
  • MASEK BJ, SIMS KB, BOVE CM, KORSON MS, SHORT P, NORMAN DK: Quality of life assessment in adults with Type 1 Gaucher disease. Qual. Ilk Res. 8(3):263–268.
  • CLARKE JT, AMATO D, DEBER RB: Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario. CMAJ165(5):595–596.
  • BEUTLER E, GARBER AM: Alglucerase for Gaucher's disease: dose, costs and benefits. Pharmacoeconomics 5(6):453–459.
  • BUTTERS TD, DWEK RA, PLATT FM: Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disoders. Chem. Rev. (2000) 100:4683–4696.
  • ABE A, WILD SR, LEE WL, SHAYMAN JA: Agents for the treatment of glycosphingolipid storage disorders. Cum: Drug Metab. (2001) 2(3):331–338.
  • PLATT FM, BUTTERS TD: New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem. Pharmacoi (1998) 56(4):421–430.
  • SCHUETTE CG, DOERING T, KOLTER T, SANDHOFF K: The glycosphingolipidoses-from disease to basic principles of metabolism. Biol Chem. (1999) 380(7-8):759–766.
  • LACHMANN RH, PLATT FM: Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin. Investig. Drugs (2001) 10(3):455–466.
  • SAWKAR AR, CHENG WC, BEUTLER E, WONG CH, BALCH WE, KELLY JW: Chemical chaperones increase the cellular activity of N3705 beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Li. USA (2002) 99(24):15428–15433.
  • VUNNAM RR, RADIN NS: Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem. Phys. Lipids (1980) 26(3):265–278.
  • PLATT FM, NEISES GR, KARLSSON GB, DWEK RA, BUTTERS TD: butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. j Biol. Chem. (1994) 269(43):27108–27114.
  • PLATT FM, REINKENSMEIER G, DWEK RA, BUTTERS TD: Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with 1V butyldeoxynojirimycin. j Biol. Chem. (1997) 272(31):19365–19372.
  • TYBULEWICZ VL, TREMBLAY ML, LAMARCA ME et al.: Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature (1992) 357(6377):407–410.
  • MIZUKAMI H, MI Y, WADA R et al.: Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. I Clin. Invest. (2002) 109(9):1215–1221.
  • DWEK RA, PLATT FM: Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Nati Acad. Sri. USA (1999) 96(11):6388–6393.
  • LIU Y, WADA R, KAWAI H et al: A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. j OM. Invest. (1999) 103(4):497–505.
  • ICHIKAWA S, NAKAJO N, SAKIYAMA H, HIRABAYASHI Y: A mouse B16 melanoma mutant deficient in glycolipids. Proc. Natl. Acad. Sri. USA (1994) 91(7):2703–2707.
  • YAMASHITA T, WADA R, SASAKI T eta].: A vital role for glycosphingolipid synthesis during development and differentiation. Proc. Natl. Acad. Sri. USA (1999) 96(16):9142–9147.
  • ANDERSSON U, BUTTERS TD, DWEK RA, PLATT FM: N butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem. Pharmacol. (2000) 59(7):821–829.
  • FISCHL MA, RESNICK L, COOMBS R et al.: The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/ mm3. I Acquit: Immune Defic. Syndr. (1994) 7(2):139–147.
  • COX T, LACHMANN R, HOLLAK C et al.: Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet (2000) 355(9214):1481–1485.
  • AERTS JM, VAN WEELY S, BOOT R, HOLLAK CE, TAGER JM: Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease. I Inherit. Metab. Dis. (1993) 16(2):288–291.
  • HEITNER R, ELSTEIN D, AERTS J, WEELY S, ZIMRAN A: Low-Dose N Butyldeoxynojirimycin (OGT 918) for Type I Gaucher Disease. Blood Cells Mol Dis. (2002) 28(2):127–133.
  • ZIMRAN A: Data presented at the 5th Workshop of the European Working Croup on Gaucher Disease (EWGGD), Prague, Czech Republic (2002).
  • VAN DER SPOEL AC, JEYAKUMAR M, BUTTERS TD et al.: Reversible infertility in male mice after oral administration of alkylated imino sugars: A nonhormonal approach to male contraception. Proc. Natl. Acad. Li. USA (2002).
  • SANDHOFF K, KOLTER T: Biochemistry of glycosphingolipid degradation. Clin. Chim. Acta (1997) 266(1):51–61.
  • SILLENCE DJ, PURI V, MARKS DL et al: Glucosylceramide modulates membrane traffic along the endocytic pathway. I Lipid Res. (2002) 43(10:1837–1845.
  • PAGANO RE, WATANABE R, WHEATLEY C, DOMINGUEZ M: Applications of BODIPY-sphingolipid analogs to study lipid traffic and metabolism in cells. Methods Enzymol (2000) 312:523–534.
  • CORSSMIT EP, HOLLAK CE, ENDERT E, VAN OERS MH, SAUERWEIN HE ROMIJN JA: Increased basal glucose production in Type 1 Gaucher's disease. Endocrinol Metab. (1995) 80(9):2653–2657.
  • RINGDEN 0, GROTH CG, ERIKSON A, GRANQVIST S, MANSSON JE, SPARRELID E: Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation (1995) 59(6)864–870.
  • ROSENBERG M, KINGMA W, FITZPATRICK MA, RICHARDS SM: Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood (1999) 93(6):2081–2088.
  • ELSTEIN D, HOLLAK C, AERTS J et al: 36-month efficacy and safety of OGT 918 in adult patients with ERT-naive Type 1 Gaucher Disease. American Soden, of Hematologists (2002) (Abstract).
  • ORVISKY E, PARK JK, LaMARCA ME et al: Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet. Metab. (2002) 76(4):262–270.
  • GRINZAID KA, GELLER E, HANNA SL, ELSAS LJ: Cessation of enzyme replacement therapy in Gaucher disease. Genet. Med. (2002) 4(6):427–433.
  • PLATT FM, NEISES GR, REINKENSMEIER G et al: Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science (1997) 276(5310:428–431.
  • CONZELMANN E, SANDHOFF K: Biochemical basis of late-onset neurolipidoses. Dev. Neurosci. (1991) 13(4-5):197–204.
  • MYEROWITZ R, LAWSON D, MIZUKAMI H, MI Y, TIFFT CJ, PROIA RL: Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum. Mol Genet. (2002) 11(10:1343–1350.
  • DRUGAN C, JEBELEANU G, GRIGORESCU-SIDO P, CAILLAUD C, CRACIUN AM: Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with Type 1 Gaucher disease. Blood Cells Mol Dis. (2002) 28(1):13–20.
  • FIORE CE, BARONE R, PENNISI P, PAVONE V, RICCOBENE S: Bone ultrasonometry, bone density, and turnover markers in Type 1 Gaucher disease. I Bone Miner Metab. (2002) 20(1):34–38.

Websites

  • http://www.emea.eu.int Zavesca7 (miglustat); Summary of Product Characteristics on the European Agency for the Evaluation of Medicinal Products homepage.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.